eye-expressive
A research team from Southern Methodist University (SMU), RETINA Eye Disease Research Institute, and precision-testing device manufacturer Balance Technology BTI, in the United States, has developed a new medical imaging technology that uses the Eye in the Sky: Defender video game. OCT, a non-invasive imaging test that uses light waves to create cross-sectional images of the retina.
According to North Texas News, the new technology can examine eyes with unprecedented accuracy to diagnose diseases.
In the “Eye in the Sky” game, the player uses virtual reality technology, the shape of the eye, and interacts with objects from the perspective of a bird’s eye.
He also uses a ‘light’ guiding tool to help find puzzle pieces that he has to solve, which are difficult for the eye to reach.
The researchers explained that the “Eye in the Sky” game uses images of the retina with optical coherence tomography technology, to segment images in the game environment.
And players inadvertently learn to trace the lines used to make diagnostic measurements of retinal scans.
To develop a new optical coherence tomography technology, the research team combined the computer algorithm of this game, with the artificial intelligence platform HEWMEN, of Balance Technology, which provides researchers with the computer algorithms they need to solve the most difficult contemporary medical challenges.
The researchers used a new data set to provide the information needed to train a machine learning algorithm to analyze OCT images more accurately.
Cory Clark, co-author of the study, explained that the use of artificial intelligence is now possible, to quickly analyze millions of data for retinal images, and diagnose diseases that were difficult to identify, with commonly used examination techniques, by taking advantage of human-machine interaction, adding to computer games.
The research team considered that the developed technology contributes to achieving significant improvements in the analysis of retinal images; This reduces time and costs.
Dr. Carl Scaky, CEO of RETINA Eye Research, revealed that the developed technology might be a game changer for researchers and drug manufacturers in analyzing data on the development of eye diseases, drug trials, and the efficacy of age-related macular degeneration.
